Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Reopening after COVID-19 lockdown and impact on disease

The study shows that 8 of 11 European countries had significantly more cases after reopening, but Germany, the UAE, and Poland had fewer. In five of the eight, the cases increased, peaked, and then dropped before the reopening happened, while Romania and Serbia showed a rapid rise before reopening.

10 Aug 2020

SARS-CoV-2 droplets travel further and last longer than thought, and even more in humid air

The ongoing COVID-19 pandemic is spread by respiratory aerosols, in which tiny droplets of saliva and mucus containing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are expelled from the upper respiratory tract. Though quite a few studies have investigated the viral load of such droplets, not much is known about how far these droplets move or how long they linger in the air, even though such information is crucial to determining how infectious they are.

10 Aug 2020

Planning low-risk school re-opening in the U.S.

With the rapid and extensive spread of the COVID-19 pandemic, the USA witnessed an almost universal closure of schools in March 2020. Now, after months of enforced online schooling, federal authorities are impatient for schools to re-open. However, how should this be done without endangering the lives of teachers, administrative and other non-teaching staff, and students at school, and parents/other family members at home?

10 Aug 2020

People may have a pre-existing immune response to COVID-19 thanks to common colds

Now, a new study shows that some people have immune responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, thanks to how the body reacted the last time it caught a cold. This means that even if a person has not been exposed to the novel coronavirus, the body has a memory of it and can trigger an immune response to fight the infection.

10 Aug 2020

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

As the coronavirus vaccine race charges on, many of the investigational candidate vaccines are nearing the final stages of human trials. The results of these trials will determine if they will be granted the green light to manufacture and distribute the vaccine to countries across the globe.

10 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

USA the source of most of New Zealand's coronavirus cases

New Zealand, an island country in the southwestern Pacific Ocean, is marked by its early and fierce determination to totally arrest the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral illness that is causing the current COVID-19 pandemic.

9 Aug 2020

How have non-pharmaceutical interventions helped in COVID-19?

The COVID-19 pandemic shows no signs of abating, with outbreaks in many spots still occurring across the world. From the start, health organizations and governments were focused on implementing non-pharmaceutical interventions (NPIs) in the absence of any effective antivirals or vaccines.

9 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

Community-based sampling needed for COVID-19 control, say researchers

Researchers in the UK have warned that it will be essential to carry out community-based sampling in addition to symptomatic testing if the ongoing transmission of severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) is going to be properly understood and controlled.

9 Aug 2020

Humans promote diseases from the animal kingdom

The coronavirus pandemic, which has now infected nearly 19 million and killed more than 712,000 people, most likely originated from bats. Just like other coronavirus outbreaks in the past, a spill-over event or zoonosis caused the viruses to jump from animals to humans.

6 Aug 2020

Study shows recombination among SARS-CoV-2 strains is already occurring, but remains rare

A recent study by U.S. researchers, currently available on the bioRxiv preprint server, indicates that the recombination events among the viral strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are already occurring – however, considering current levels of viral genetic diversity, they are neither widespread nor readily detectable.

6 Aug 2020

Heat suggested as a therapeutic intervention in COVID-19

Viruses that are contained within a lipid membrane or “enveloped viruses” such as coronaviruses and rhinoviruses can remain active for long periods in cool, dry conditions, which can lead to increased rates of respiratory infections.

6 Aug 2020

COVID-19 in pregnancy - premature birth common

A new study conducted by researchers at Yonsei University College of Medicine, Korea, suggests that while having coronavirus disease 2019 (COVID-19) during pregnancy has little effect on fetal or neonatal mortality, it can be associated with premature birth and sometimes severe outcomes for mother and baby, including death.

6 Aug 2020

Human encroachment into forest land caused bat CoV spillover and COVID-19 emergence

A new study published on the preprint server medRxiv in August 2020 discusses the root causes underlying the emergence of such infectious diseases following their crossover of the line separating animal viruses from human. This initial event is of enormous significance.

6 Aug 2020

Face masks protect from COVID-19 and other respiratory illnesses

Now a new study published on the preprint server medRxiv in August 2020, therefore, presents the results of a meta-analysis that takes account of the lack of compliance with mask-wearing in RCTs, as well as the lag between the event and the measurable effects.

6 Aug 2020

Cats susceptible to and potential reservoirs for novel coronavirus

The study published on the preprint server bioRxiv in August 2020 shows that this is indeed taking place, with pet cats being infected and passing on the infection to contacts. It also offers the chance to see how the disease progresses in a susceptible host.

6 Aug 2020